Compare Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.82 (market cap $158.90B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 21.1× Spyre Therapeutics Inc. Common Stock's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.35% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SMFG | SYRE | |
|---|---|---|
Market Cap | $158.90B | $7.52B |
Volume | 1,175,519 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $27.56 | $108.92 |
52-Week Low | $15.69 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.70T | $6.52B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMFG trades at $25.21, up 0.72% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beating expectations with $0.50 EPS versus $0.44 expected, while Q4 2025 missed estimates. Revenue grew from $5.07T in 2025 to $6.14T in 2026 with net income margin improving to 27.8%. Analyst consensus shows 75% hold rating with institutional positions shifting recently.
SMFG presents a value opportunity with attractive valuation ratios (P/E 14.9, EV/EBITDA 5.16) and improving profitability, though technical weakness and mixed analyst sentiment suggest near-term caution. The stock faces risks from Japanese interest rate sensitivity and competitive pressures in global banking markets.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
